PepGen said speech difficulties in DM1 are primarily driven by muscle weakness and myotonia in speech muscles, with fatigue further reducing clarity. The update

PepGen said speech difficulties in DM1 are primarily driven by muscle weakness and myotonia in speech muscles, with fatigue further reducing clarity. The update comes as its PGN-EDODM1 program advances into the highest-dose cohort in Phase 2.